A. McDonald - Concepedia

Author

A. McDonald

Beatson West of Scotland Cancer Centre

Also Known As

A C McDonald, A McDonald, A. C. McDonald, A. McDonald, A. Mcdonald, A.C. McDonald, AC McDonald, J. W. Valle

Publications

928

Citations

H-Index

Concepts

All Affiliations

Beatson West of Scotland Cancer Centre Western Infirmary University of Glasgow University of Oxford Cancer Research UK

About

A. McDonald is an author at Beatson West of Scotland Cancer Centre specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	332
2	Health Sciences	1	1	84
3	Anatomy	1	1	22
4	Biochemistry	1	1	84
5	Cardiothoracic Surgery	1	1	22

A. McDonald

Publications

810

Citations

H-Index

Page 1

	Year	Citations
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C David Propper, A. McDonald, A. Man, Journal of Clinical Oncology	2001	233
Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer Ross Carruthers, Lye Mun Tho, Jennifer R. Brown, Colorectal Disease	2012	136
A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. A. McDonald, P. Vasey, Lynn Adams, PubMed Pharmaceutical SciencePharmacokinetic StudyPharmacotherapyDrug ResistanceMolecular Pharmacology	1998	84
Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer Chris Hurt, Stephen Falk, Tom Crosby, British Journal of Cancer	2017	69
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma T.R. Jeffry Evans, G. Pentheroudakis, James Paul, Annals of Oncology Gastrointestinal OncologyInoperable Oesophago-gastric AdenocarcinomaMedicineMetronomic TherapyPharmacology	2002	62
Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors A. McDonald, Robert Brown British Journal of Cancer Cell DeathAnti-cancer AgentTumor SuppressorP53-independent Cellular ResponsesTopoisomerase 1	1998	55
Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Suresh Senan, R Rampling, Marien Alet Graham, PubMed Medicinal ChemistrySr 4233OncologyPharmacological StudyPharmacology	1997	48
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion James Stevenson, D Demaria, J Sludden, Annals of Oncology	1999	26
Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. John P. Neoptolemos, Malcolm J. Moore, Trevor F. Cox, Journal of Clinical Oncology Surgical OncologyGastrointestinal OncologyMedicineLba4006 BackgroundCancer Management	2011	24
Anomalous muscle bundle of the right ventricle. Its recognition and surgical treatment. M D Li, John C. Coles, A. McDonald Heart Cardiac MuscleAnomalous Muscle BundleStructural Heart DiseaseCardiac MechanicSurgical Treatment	1978	22

Page 1